Markets:

Overview

News

Currencies

International

Treasuries

Adicet Bio, Inc. - Common Stock (NQ:ACET)

8.075 +0.175 (+2.22%)

Streaming Delayed Price Updated: 3:03 PM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Adicet Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

January 07, 2026

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Announces Reverse Stock Split

December 26, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

November 28, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 05, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

October 31, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

October 28, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

October 16, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

October 07, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

October 07, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

September 30, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 02, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 29, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 07, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

August 05, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

July 24, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 21, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 06, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 30, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

April 30, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

April 28, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Appoints Michael Grissinger to the Board of Directors

April 17, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 31, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

March 31, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

March 06, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

March 03, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

February 27, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

February 05, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 31, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

January 29, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

January 08, 2025

From Adicet Bio, Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.